Business Wire

ONCOIMMUNITY

12.3.2019 18:24:09 CET | Business Wire | Press release

Share
Flow Pharma, Inc. and OncoImmunity AS partner for the Development of FlowVaxTM Personalized Cancer Vaccines

Flow Pharma Inc ., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, today announced a collaboration with Norwegian bioinformatics company OncoImmunity AS .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190312005768/en/

Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform . The Immuneoprofiler™ has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction. The FlowVax vaccine platform developed by Flow Pharma , is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma , that will work-in-sync with the Immuneoprofiler™ software to make predictions tailored to the FlowVax platform.

“This exciting partnership and licensing deal represents a fantastic opportunity for OncoImmunity to apply its Immuneoprofiler™ prediction software to the FlowVax technology in a clinical setting. It also affords OncoImmunity the opportunity to leverage its in-depth knowledge of immune-informatics and expertise in machine learning to develop a customised solution for the FlowVax platform that will support Flow Pharma’s needs now and in the years ahead” said Richard Stratford ., Chief Executive Officer at OncoImmunity.

“We believe that OncoImmunity’s Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens. Flow Pharma’s bioinformatics team will be working closely with OncoImmunity AS to customize the way we utilize Immuneoprofiler™ in order to optimize the use of the data we will be generating” said Reid Rubsamen, M.D. , CEO of Flow Pharma.

About OncoImmunity

OncoImmunity AS is a machine-learning company offering a proprietary technology to address key knowledge gaps in the prediction of bona fide  immunogenic neoantigen for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets creating truly personalized cancer vaccines & cell therapies in clinically actionable time-frames.

About Flow Pharma

Flow Pharma Inc. is a San Francisco Bay Area based, biotechnology company developing personalized neoantigen-based vaccines based on its proprietary FlowVax vaccine platform.

The FlowVax platform is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. Flow Pharma is now gearing up to test therapeutic cancer vaccines based on the FlowVax platform.

About FlowVax TM

Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. FlowVax vaccines can also be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.

However, as with all personalized vaccine approaches, the successful development and commercialisation of products based on the FlowVax platform is predicated on being able to identify clinically actionable and immunogenic neoantigen targets in a cost effective and clinically actionable time-frame. OncoImmunity’s Immuneoprofiler™ software, addresses this challenge, by harnessing the power of artificial intelligence (AI) to identify clinically relevant and immunogenic neoantigens from next generation sequencing data.

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (''the Company''), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ''believes,''''expects,''''intends,''''plans,''''anticipates,'' or ''may,'' and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.

Contact:

Trevor Clancy Ph.D. CSO OncoImmunity E-mail: trevor@oncoimmunity.com Phone: + 47 41 43 12 42

Link:

ClickThru

Social Media:

https://www.facebook.com/OncoImmunity/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release

Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta

SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release

Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release

With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release

The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release

Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye